Week 11

Cancer therapy

Lecture 26 finishes cancer by asking what a tumor must get past to become malignant. It opens with the 2018 Nobel Prize to James Allison and Tasuku Honjo for releasing a brake on the immune system so that it attacks cancer. The barriers are a body that controls division and survival through signals between cells, apoptosis as a failsafe when a cell misbehaves, the immune system, adhesion between cells, and the basement membrane under every epithelium. About 90% of cancers start in epithelial cells, which stick together and stay put, unlike migratory mesenchymal or stromal cells such as neutrophils and fibroblasts. A tumor is benign (dysplasia, adenoma) until it breaches the basement membrane and becomes a malignant carcinoma. Oncogenic mutations and loss of tumor suppressors reduce a tumor's need for growth signals but do not remove it. Tumors recruit stromal cells that feed them growth and survival signals: in a 1950s experiment, basal cell carcinoma grafted with its stroma grew but grafted without it died. The same dependence makes HER2, overexpressed in about 30% of breast cancers, a target for the antibody Herceptin. To leave the organ, cancer cells undergo an epithelial-to-mesenchymal transition. EMT is a reversible change in gene expression, driven by transcription factors such as Twist, Snail, and Slug that repress E-cadherin and turn on migration genes, and cancer borrows it from fly mesoderm development and wound healing. Migration itself runs on actin: filaments growing at their plus ends push out the leading edge, integrins anchor it to the matrix, and the cell pulls itself forward, though confined cells can move without integrins. Exam 3 (lectures 18 to 25) was on Friday of this week. There is no new reading: MIT's reading for lecture 26 was Life 11.7 continued, listed in week 10.

Objectives

  • List the body's barriers to a tumor (control of division and survival by signals from other cells, apoptosis as a failsafe, the immune system, cell-cell adhesion, the basement membrane), and tell dysplasia and a benign adenoma from a malignant carcinoma by whether cells have breached the basement membrane
  • Explain how tumors recruit stromal cells that supply growth and survival signals, what the basal cell carcinoma graft experiment with and without stroma showed, and why overexpression of the receptor tyrosine kinase HER2 in about 30% of breast cancers made the antibody Herceptin an effective treatment
  • Contrast epithelial cells (strong cell-cell adhesion through E-cadherin, little migration) with mesenchymal or stromal cells, and explain EMT as a reversible change in gene expression, driven by transcription factors such as Twist, Snail, and Slug, that cancer borrows from development and wound healing
  • Explain how G-actin polymerizes into F-actin with plus ends facing the leading edge to push out a lamellipodium, how integrins anchor the protrusion to the matrix, and how repeated protrusion, adhesion, and pulling move a cell, and note that confined cells can migrate without integrins
  • Interpret Weinberg's focus formation assay and a sequencing gel to identify the Ras glycine-to-valine change at codon 12 as a dominant gain-of-function mutation, and predict whether one mutant allele (constitutively active Alk kinase, fos lacking its nuclear localization sequence, Ras with constitutive GTPase activity) makes a cell cancerous

Lectures

26Cancer 248:38
48:38

Recitations

Recitation 17: Oncogenes, tumor suppressors, and cancer

Reviews lectures 25 and 26: cancer as an accumulation of mutations, carcinogens and the Ames test, proto-oncogenes versus tumor suppressors, viral oncogenes such as v-src from Rous sarcoma virus and HPV, and familial versus sporadic retinoblastoma. The problems cover the Ras focus formation assay, single gain- and loss-of-function alleles, two chemotherapy drugs, and loss of heterozygosity of APC.

  1. (1a) Weinberg's lab cut genomic DNA from human bladder carcinoma cells into small pieces and put the pieces into mouse 3T3 fibroblasts growing on plates. Only a cell that took up the mutant Ras allele grew and divided enough to form a focus (a colony); DNA from normal human cells gave no foci. Which describes the mutant Ras gene: (i) a proto-oncogene with a recessive loss-of-function mutation, (ii) a proto-oncogene with a dominant gain-of-function mutation, (iii) a tumor suppressor with a gain-of-function mutation, (iv) a tumor suppressor with a homozygous loss-of-function mutation, or (v) a tumor suppressor with a heterozygous loss-of-function mutation?
  2. (1b) Dideoxy sequencing gels (lanes ddA, ddG, ddC, ddT) cover the coding sequence for amino acids 10 to 14 in exon 1 of Ras. Reading the bands from the bottom (+) to the top (−), the wild-type fragment gives G G C G C C G G C G G T G T G and the mutant fragment gives G G C G C C G T C G G T G T G. Give the sequence of the template strand used to sequence each allele, and label its 5′ and 3′ ends.
  3. (1c) Is the mutation in the mutant Ras allele a frameshift, silent, nonsense, or missense mutation?
  4. (1d) Only one mutation was needed to make the 3T3 cells overproliferate, yet cancer results from an accumulation of mutations. Why did the experiment work?
  5. (2) Ras is a GTPase, active with GTP bound and inactive with GDP bound, in a pathway whose input is an extracellular growth factor and whose output is transcription of genes needed for the cell cycle. A cell has one wild-type RAS allele and one mutant allele with constitutively active GTPase activity. Would the cell be cancerous? Why or why not?
  6. (3) A single copy of each mutant gene is introduced, separately, into an immortalized non-cancerous cell line: fos, which normally encodes a transcription factor that promotes proliferation, mutated so its product lacks the nuclear localization sequence; and Alk, which normally encodes a tyrosine kinase that promotes cell cycle progression, mutated so its kinase domain is constitutively active. For each, say whether the wild-type gene is a proto-oncogene or a tumor suppressor and whether the cell with one mutant copy is cancerous or non-cancerous.
  7. (4) Methotrexate inhibits thymidine synthesis, and cisplatin crosslinks double-stranded DNA. For each drug, choose the process it inhibits (replication, transcription, protein synthesis, or division) and explain.
  8. (5a) Familial adenomatous polyposis (FAP), which affects about 1 in 8,000 people in the USA, predisposes to colon cancer through mutations in APC. Gels compare PCR-amplified APC DNA and APC protein from white blood cells (WBCs) and colon cells. A normal individual has one full-length DNA band in both WBCs and colon cells, and full-length protein only in colon cells. Individual 1 has a faint full-length band and a faint shorter band in WBC DNA, only the shorter band (strong) in colon cancer DNA, and a shorter protein in the cancer cells. Individual 2 has only the full-length band (strong) in WBC DNA, only the shorter band in colon cancer DNA, and a shorter protein in the cancer cells; no APC protein appears in any WBC sample. Why does the normal individual have APC protein only in colon cells when both cell types carry APC DNA?
  9. (5b) From the same gels, one of the two individuals does not have FAP but still develops colon cancer. Which one, and how did that person get colon cancer?
  10. (5c) From the same gels, give the APC genotype in WBCs and in colon or colon cancer cells for the normal individual and for individuals 1 and 2, using + for wild type, − for loss of function, and M for gain of function, and explain any difference between WBCs and cancer cells.